NOVN arrives at its Q1 2026 results today with one of the most striking setup features being the near-complete retreat of short sellers over the past six weeks.
Short interest has collapsed. The SI % of free float has fallen from a local high near 1.1% in mid-March to just 0.15% — a decline of roughly 86% in under six weeks. Utilization tells the same story: it peaked at 8.2% on March 16 and has since dropped to 1.6%, the lowest reading of the past year. Borrow costs have eased in parallel, sliding to 0.60% from above 0.90% a month ago. With availability running at almost 70x the current short interest, there is no meaningful short-side pressure heading into the print.
The broader debate for Novartis is whether recent price weakness reflects a valuation reset or genuine concern about the pipeline and margins. The stock has dropped 4.2% over the past month to CHF 114.08 — underperforming peers on the week, with AZN off 7.7%, GSK down 5.8%, and MRK falling 6%. That relative resilience is notable in a sector under broad selling pressure. The analyst consensus mean target of CHF 154 implies substantial upside from current levels, though no recent price-target changes were recorded in the run-up, leaving that gap to the print itself to address. The PE multiple has compressed roughly 0.7 turns over the past month to 15.7x, while EV/EBITDA has come in to 12.4x — both modest by large-cap pharma standards. The dividend score ranks in the 90th percentile, reflecting the company's track record as a reliable income name.
The ownership and insider picture is less supportive. Insiders registered net sales of roughly $42 million over the past 90 days, concentrated in late January and early February near CHF 117-127 — levels above where the stock trades today. The largest single disclosed sale in March, worth over $11 million, came from a non-executive board member. Institutional holders are largely passive index-oriented names; UBS Asset Management, Vanguard, and the Sandoz Family Office collectively hold around 16% of shares, with no material additions flagged recently.
The Q1 print is therefore less a test of whether Novartis is growing — the short squeeze and valuation re-rating from earlier in the year already embed that — and more a question of whether the company can sustain operating momentum at a margin profile that justifies the gap between current price and analyst targets, in a macro environment that has weighed on the whole sector.
See the live data behind this article on ORTEX.
Open NOVN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
